Vertex Pharmaceuticals (NASDAQ:VRTX) Raised to "Strong-Buy" at Truist Financial

Key Points

• Truist upgraded Vertex to a Strong-Buy and raised its price target to $525 after encouraging Week‑36 interim results from the Phase 3 RAINIER study, marking a near‑term positive catalyst.
• Analyst sentiment remains broadly bullish — one Strong Buy, 23 Buy and five Hold lead to a MarketBeat consensus of Moderate Buy with an average price target of $554.30, while the stock trades around $455 and has a $115.6B market cap.
• Vertex slightly missed EPS ($5.03 vs. $5.05) but beat revenue ($3.19B) with 9.5% YoY revenue growth and solid margins, though insiders sold roughly $44M of shares over the past three months.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) was upgraded by investment analysts at Truist Financial to a "strong-buy" rating in a research report issued on Wednesday,Zacks.com reports.

VRTX has been the topic of a number of other reports. Wolfe Research raised shares of Vertex Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $548.00 price objective on the stock in a research report on Tuesday, January 6th. Jefferies Financial Group started coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, March 10th. They issued a "buy" rating and a $580.00 target price for the company. Bank of America lifted their target price on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the company a "buy" rating in a research note on Tuesday, March 10th. Leerink Partners upped their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an "outperform" rating in a research note on Monday, December 29th. Finally, Sanford C. Bernstein reiterated an "outperform" rating and set a $577.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $554.30.

Vertex Pharmaceuticals Trading Up 1.4%

Shares of Vertex Pharmaceuticals stock opened at $454.97 on Wednesday. Vertex Pharmaceuticals has a 1 year low of $362.50 and a 1 year high of $510.77. The company has a market cap of $115.58 billion, a P/E ratio of 29.68, a P/E/G ratio of 1.92 and a beta of 0.31. The stock has a 50-day moving average price of $468.97 and a 200 day moving average price of $441.56.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to analysts' expectations of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company's revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm earned $3.98 EPS. On average, equities analysts forecast that Vertex Pharmaceuticals will post 15.63 earnings per share for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 260 shares of the firm's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $126,451.00. Following the transaction, the executive vice president owned 46,763 shares in the company, valued at approximately $22,743,185.05. This trade represents a 0.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Duncan Mckechnie sold 4,910 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the completion of the sale, the executive vice president directly owned 17,559 shares of the company's stock, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 93,485 shares of company stock valued at $43,967,586. Insiders own 0.20% of the company's stock.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Chesapeake Asset Management LLC lifted its position in shares of Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company's stock worth $25,000 after purchasing an additional 33 shares during the last quarter. Motiv8 Investments LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at approximately $26,000. Colonial Trust Co SC increased its position in Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 38 shares during the period. Swiss RE Ltd. bought a new position in Vertex Pharmaceuticals in the 4th quarter worth approximately $28,000. Finally, Eagle Bay Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $29,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Truist raised its price target on Vertex to $525 (from $490) and kept a Buy rating after encouraging Week‑36 interim results from Vertex’s Phase 3 RAINIER study — a clear positive catalyst supporting higher upside expectations. Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results
• Positive Sentiment: Multiple bullish writeups and retail/investor attention argue VRTX remains a buy—analysts and commentators point to durable CFTR franchise cash flows, pipeline upside and the recent dip as a potential buying opportunity. Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?
• Neutral Sentiment: Zacks and market headlines note VRTX outperformed the broader market in the latest session and is drawing elevated attention from Zacks users — this likely amplified buying interest but is descriptive rather than a fresh fundamental shift. Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here's Why
• Neutral Sentiment: Reports of large short‑interest changes are inconsistent/placeholder in recent feeds (reported zeros/NaN), so there’s no clear short‑squeeze signal — effectively neutral on near‑term price pressure.
• Negative Sentiment: Competition risk: Maze Therapeutics reported positive Phase II data for an APOL1‑mediated kidney disease drug that targets the same pathway Vertex is pursuing — the news highlights competitive risk to Vertex’s AMKD franchise, which could weigh on long‑term upside if competitors advance. Maze tumbles despite positive data for kidney disease drug

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.